1. Home
  2. CTOS vs GYRE Comparison

CTOS vs GYRE Comparison

Compare CTOS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Custom Truck One Source Inc.

CTOS

Custom Truck One Source Inc.

HOLD

Current Price

$6.01

Market Cap

1.4B

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.13

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTOS
GYRE
Founded
1988
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
755.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CTOS
GYRE
Price
$6.01
$7.13
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$7.33
$17.00
AVG Volume (30 Days)
740.4K
88.6K
Earning Date
10-27-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.04
Revenue
$1,936,513,000.00
$107,265,000.00
Revenue This Year
$13.19
$11.59
Revenue Next Year
$4.90
$26.31
P/E Ratio
N/A
$183.44
Revenue Growth
7.39
2.13
52 Week Low
$3.18
$6.11
52 Week High
$6.78
$14.42

Technical Indicators

Market Signals
Indicator
CTOS
GYRE
Relative Strength Index (RSI) 47.66 39.55
Support Level $5.89 $6.92
Resistance Level $6.10 $7.39
Average True Range (ATR) 0.23 0.36
MACD -0.03 -0.08
Stochastic Oscillator 57.41 17.24

Price Performance

Historical Comparison
CTOS
GYRE

About CTOS Custom Truck One Source Inc.

Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: